A modified comorbidity index for hematopoietic cell transplantation

Bone Marrow Transplantation

Volumn 45, Issue 5, 2010, Pages 933-938

  Defor, T E ^a   Majhail, N S ^a   Weisdorf, D J ^a   Brunstein, C G ^a   McAvoy, S ^a   Arora, M ^a   Le, C T ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Comorbidity; Index; Transplant

Indexed keywords

BUSULFAN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MODIFIED COMORBIDITY INDEX; OVERALL SURVIVAL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; COMORBIDITY; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 77952428970     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.275     Document Type: Article

References (17)

1. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretansplantation comorbidities. Blood 2004;204:960-968.
2. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006;12:954-964.
3. Alamo J, Shahjahan M, Lazarus HM, de Lima M, Giralt SA. Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Bone Marrow Transplant 2005;36:473-474.
4. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2911-2919.
5. Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG, Deeg HJ. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007;110:4606-4613.
6. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007;25:4246-4254.
7. Majhail NS, Brunstein CG, McAvoy S, DeFor TE, Al-Hazzouri A, Setubal D et al. Does the hematopoietic-cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant 2008;14:985-992.
8. Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplant outcomes in 110 adults with hematological disease. Blood 2007;8:3064-3070.
9. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005;105:1343-1347.
10. Flynn CM, Hirsch B, Defor T, Barker JN, Miller JS, Wagner JE et al. Reduced intensity compared with high dose conditioning for allo transplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol 2007;82:867-872.
11. Majhail NS, Weisdorf DJ, Wagner JE, Defor TE, Brunstein CG, Burns LJ. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 2006;107:3804-3807.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
13. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997;16:901-910.
14. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
15. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
16. Harrell FE, Caoliff RM, Pryor DB, Lee LK, Rosati RA. Evaluating the yield of medical tests. J Am Med Assoc 1982;247:2543-2546.
17. Efron E, Tibshirani RJ. An Introduction to the Bootstrap. Chapman & Hall, Inc.: New York, NY, USA, 1993.